CBSA’s Policy + Advocacy team continues to focus on policy priorities critical to our ecosystem in the remaining weeks of the Colorado legislative session. With just over two weeks left, CBSA has taken a position on thirty-six bills, supporting six, opposing two, and monitoring the rest. Some of CBSA’s priorities are moving forward, while others are not. Two noteworthy events from the past week are that:
- A favorable amendment was added to HB23-1225, Extend And Modify Prescription Drug Affordability Board, which CBSA still opposes, and
- HB23-1110, Health-care Coverage For Biomarker Testing, which CBSA supports, effectively reached the end of its road for this year.
HB23-1225: Extend and Modify Prescription Drug Affordability Board
HB23-1225 extends and expands the Prescription Drug Affordability Board (PDAB) established in 2021 (SB21-175) by…
Click here to view original post
